



Best of WCLC Supportive Care 2024

Kavitha Ramchandran MD

Clinical Professor

10.5.2024





What we will cover

- Meet the Expert
 - Jennifer Temel and Cristiane Bergerot, PhD and Technology Based Interventions to Support Patients with Cancer
- Oral Abstracts
 - Music
 - Care for Older Adults with Lung Cancer
 - New Models to expedite referrals to supportive care



Background

- Guidelines recommend integrated palliative care into oncology care

BUT

- Patients have challenges making extra visits to PC
- PC has significant shortages in providers and clinic time

SO

- Digital health may be the answer



DREAMLAND Digital Health Application

- An educational and interactive journey as patients navigate their hospitalization.
- Self-administered with features to promote engagement and health behavior change.
- Incorporates components of cognitive behavioral therapy to foster effective coping.



DREAMLAND

Module 1
86.2% complete

Module 2
75.9% complete

Module 3
62.1% complete

Module 4
51.7% complete

Time Spent Mean (SD)	Time Spent Mean (SD)	Time Spent Mean (SD)	Time Spent Mean (SD)
22.8 minutes (13.5)	21.0 minutes (13.5)	14.6 minutes (5.6)	10.7 minutes (3.9)

TABLE 2 Effect of DREAMLAND on patient-reported outcomes at day 20 after intensive chemotherapy

Day +20	Sample size	Group assignment	Adjusted mean score	95% CI	p	Cohen d
QoL (FACT-Leukemia)	53	Usual care	110.72	103.23–118.20	.001	0.89
		Mobile app	132.06	124.14–139.99		
Anxiety symptoms (HADS-Anxiety)	53	Usual care	5.64	4.57–6.7	.010	0.60
		Mobile app	3.54	2.40–4.69		
Depression symptoms (HADS-Depression)	53	Usual care	6.29	4.95–7.64	.121	0.39
		Mobile app	4.76	3.33–6.18		
PHQ-9 depression symptoms	53	Usual care	8.35	7.06–9.65	< .001	0.89
		Mobile app	4.62	3.22–6.03		
Symptom burden (ESAS)	53	Usual care	40.60	32.83–48.38	.007	0.69
		Mobile app	24.89	16.79–32.98		
Self-efficacy (CASE)	53	Usual care	135.43	127.90–142.94	.004	0.69
		Mobile app	151.84	143.86–159.82		




THRIVE Digital Health App

- Developed based on the data that early palliative care improves quality of life and our data about the importance of coping in driving the benefits of palliative care.
 - Modules mirror the domains of quality of life.
 - Coping strategies integrated throughout.




THRIVE Pilot Trial Results

- 70.5% (43/61) of patients assigned to THRIVE completed \geq four of the six modules.
- 77.3% reporting above-average usability ratings for THRIVE.



THRIVE Randomized Trial






Oral Abstracts:

- OA 07.03- The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients
- OA07.04 - Optimising Care of Older Patients with Lung Cancer – An Innovative Nurse-Led Model of Care
- OA07.05- Improving Supportive and Social Care in Lung Cancer with the 4R Oncology Model for Patient Care Planning and Delivery



Abstract OA07.03 The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients

MLH II Study Design



Primary endpoint

- Oxycodone-weight Ratio

Secondary endpoints

- VAS-P scores
- VAS-A scores
- Rescue analgesia times
- EORTC QLQ-C30 scores

Exploratory endpoint

- β -band power

- A target sample size of 66 patients provided 80% power to detect an absolute SMD of 0.4, corresponding to a reduction in oxycodone-weight ratio and with 10% drop-out rate

MLH, Music of Lung Health; NSCLC, non-small-cell lung cancer; AJCC, American Joint Committee on Cancer; WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group; PS, performance status; R, randomized; IBP, intensity-based personalized; PCIA, patient controlled intravenous analgesia; VAS-P, visual analogue scale for pain; VAS-A, visual analogue scale for anxiety; EORTC, European Organization For Research And Treatment Of Cancer; QLQ-C30, core quality of life questionnaire; ^a PCIA pump setting: 1mg/kg oxycodone, background infusion of 1.5ml/h, bolus dose of 1.8ml, lockout interval 5 minutes, maximum dose of 15ml/h



Baseline characteristics in the mITT population



	IBP Music Therapy (n=39)	Standard Care (n=22)
Age, n (%)		
< 60 years	15 (38.5)	12 (54.5)
≥ 60 years	24 (61.5)	10 (45.5)
Male, n (%)	19 (48.7)	10 (45.5)
ECOG PS, n (%)		
0	36 (92.3)	20 (90.9)
1	3 (7.7)	2 (9.1)
Disease stage, n (%)		
I	30 (76.9)	15 (68.2)
II	4 (10.3)	1 (4.5)
III	5 (12.8)	6 (27.3)
Smoking status, n (%)		
Current/Former	18 (46.2)	10 (45.5)
Never	21 (53.8)	12 (54.5)

SD, standard deviation; VATS, video-assisted thoracoscopic surgery; RATS, robotic-assisted thoracoscopic surgery; SAS, Self-Rating Anxiety Scale; QoL, Quality of Life; IQR, interquartile range; ^a Evaluated on the admission day; ^b Assessed by brief pain inventory questionnaire

	IBP Music Therapy (n=39)	Standard Care (n=22)
Surgical type, n (%)		
VATS/RATS	36 (92.3)	21 (95.5)
Open surgery	3 (7.7)	1 (4.5)
Resection area, n (%)		
Sublobe (e.g. wedge, segment)	19 (48.7)	3 (13.6)
Lobe	20 (51.3)	19 (86.4)
Educational background, n (%)		
Below middle school	22 (56.4)	15 (68.2)
High school	12 (30.8)	3 (13.6)
College or above	5 (12.8)	4 (18.2)
Median SAS^a (IQR)	42.5 (35.6-46.3)	41.3 (36.6-44.7)
Median VAS-A^a (IQR)	3 (1-5)	3 (3-5.8)
Median QoL^a (IQR)	6 (3-9.5)	5 (5-8)
Chronic pain history^{a,b}, n (%)		
Yes	11 (28.2)	4 (18.2)
No	28 (71.8)	18 (81.8)



Primary Endpoint: Oxycodone-Weight Ratio





	Intensity-based Personalized Music Therapy (n=39)	Standard Care (n=22)
Mean Oxycodone-Weight Ratio ^c , mg/kg (SD)	1.00 (0.44)	1.38 (0.33)
Standardized Mean Difference (95% CI) ^a	-0.93 (-1.48, -0.38)	
P value ^d	<0.001	



SD, standard deviation; SMD, standardized mean difference; ^a Cohen's d; ^b clinical stage; ^c PCIA pump was stopped at 48 hours after first dose and the amount of oxycodone was calculated ^d independent-samples t test

Secondary Endpoints: Pain Assessment





	IBP Music Therapy (n=39)	Standard Care (n=22)
Rescue Analgesia Requirement (%) ^a	14.7	45.5
Relative Risk (95% CI)	0.63 (0.42, 0.93)	
P value ^b	0.004	

	0 hour ^c		24 hours		48 hours	
	IBP-MT (n=39)	SC (n=22)	IBP-MT (n=39)	SC (n=22)	IBP-MT (n=39)	SC (n=22)
Median VAS-P Scores (IQR)	1 (1-2)	1 (1-1.3)	2.3 (1.7-4)	3.4 (2.3-4.7)	1.3 (0.7-2)	3.4 (2.1-4.1)
P value ^d	0.802		0.04		<0.001	

^a Proportion of patients who used extra opioids with 48 hours after surgery; ^b Chi-squared test; ^c start from traveling to recovery room and fully awaked after surgery; ^d Mann-Whitney *U* Test



Secondary Endpoints: Anxiety Assessment



	Before Treatment		After Treatment		Operation Room		0 hour ^a		24 hours		48 hours		60 hours	
	IBP-MT (n=39)	SC (n=22)	IBP-MT (n=39)	SC (n=22)	IBP-MT (n=39)	SC (n=22)	IBP-MT (n=39)	SC (n=22)	IBP-MT (n=39)	SC (n=22)	IBP-MT (n=39)	SC (n=22)	IBP-MT (n=39)	SC (n=22)
Median VAS-A Scores (IQR)	3 (2-4)	3 (2.25-3.75)	1.5 (0-3)	3 (1.25-4.75)	2 (1-3.5)	5 (3-5)	3.3 (2.5-3.67)	3.2 (2-4)	1.67 (0.67-2)	2.83 (1.75-4)	0.67 (0-1.67)	3 (1.55-3.75)	2 (0-2)	3 (0.75-4.25)
P value^b	0.79		0.045		0.042		0.83		0.003		<0.001		0.0294	

^a start from traveling to recovery room and fully awaked after surgery; ^b Mann-Whitney U Test

Conclusions

- MLH (Music of Lung Health) II study showed that intensity-based personalized music therapy has significant **effect of pain-relieving**
 - Lower oxycodone-weight ratio (1 vs 1.83 mg/kg, SMD, -0.93)
 - Lower rescue analgesia requirement (14.7% vs 45.5%, RR, 0.63)
 - Lower VAS-P scores (24 hours, median, 2.3 vs 3.4; 48 hours, 1.3 vs 3.4)
- Intensity-based personalized music therapy also has great **effect of anxiety-reducing**
 - Lower VAS-A scores (Pre-operation, median, 1.5 vs 3; 24 hours, 1.67 vs 2.83; 48 hours, 0.67 vs 3; 60 hours, 2 vs 3)
- Intensity-based personalized music therapy can **effectively alleviate dyspnea symptom** in the rehabilitation period by reducing anxiety status
 - Lower dyspnea scores (26.3 vs 41.2, SMD, -3.3)
 - Mediation effect (Indirect effect, 9.36)
- The positive correlation between changes of β -band power in the central brain area and VAS-A scores objectively prove the anxiety-reducing effect of intensity-based personalized music therapy ($r = 0.4$)



SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

Abstract OA07.03 “The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients”

Strengths

- Clinically significant findings in pain reduction w/IMB vs SC
- Statistically significant reduction in anxiety at 48 hrs in IMB vs SC

Considerations


- 2:1 Randomization
- More individuals w/chronic pain hx in IBMT

Future Opportunities

- 1:1 Randomization
- Additional co-morbidities



Oncology challenges in older patients



Geriatric Assessment in Cancer



↑ treatment completion



↑ QOL



↓ Hospitalisations/ ED presentations




↓ Grade 3 Toxicities



Disalvo D et al JGO 2023

Nurse led multidisciplinary model of care in older patients with lung cancer


PATHWAY OF MANAGEMENT



Issues identified


Referrals made

Results – 6m






Pts discussed at GOMOC MDT



Pts seen prior to Treatment



Referred for Comprehensive Geriatric Assessment



Pts seen on same day as oncologist visit




Pts were satisfied with the MOC



Pts agree the MOC was acceptable

Medical-Led GOMOC vs Nurse-Led GOMOC



Conclusions & Future Directions

- Nurse-Led GOMOC increased the proportion of older patients with lung cancer undergoing geriatric screening and assessment
- This model of care was highly acceptable to patients and carers
- Future plans
 - Comparison of hospitalisations/ ED presentations / Gd 3+ toxicities / Rx discontinuation with Medical-Led GOMOC and historical controls
 - Cost Nurse-Led GOMOC



SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

Abstract OA07.04 “Optimising Care of Older Patients with Lung Cancer – An Innovative Nurse-Led Model of Care”

Strengths

- Co-designed by ALL stakeholders
- Nurse led program effective in increasing eligible patients seen, screened, assessed

Considerations

- Average time per patient
- Utilize eHealth for G8/HADS/GDS

Future Opportunities


- Expand program throughout Cancer Center
- Implement Geriatric ONN/CNS



Abstract OA07.05 Improving Supportive and Social Care in Lung Cancer with the 4R Oncology Model for Patient Care Planning and Delivery

Methods:

- Surveys of control cohort of patients who received care pre-4R (N=112)
- Implemented Care Sequence[®] plans
- Surveys of 4R cohort of patients who received these plans along with care (N=61)
- Analyzed 7 supportive and social care metrics for referral and completion of referral



SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

Background:

- It is difficult to identify and address the supportive and social care needs of patients with NSCLC
- The 4R Oncology[®] Model facilitates timely delivery of comprehensive care through 4R Care Sequence[®] plans
- 4R Oncology[®] model was implemented at 8 centers (4 community, 3 academic, 1 VA) and evaluated its impact on referrals to and receipt of supportive & social care in NSCLC.

4R (Right Information/Care/Patient/Time)



Methods:

- Surveys of control cohort of patients who received care pre-4R (N=112)
- Implemented Care Sequence[®] plans
- Surveys of 4R cohort of patients who received these plans along with care (N=61)
- Analyzed 7 supportive and social care metrics for referral and completion of referral

Care Sequence[®]: Cancer Drug Therapy before surgery

Name _____ DOB _____ MRN _____ Today's Date _____

Goal of Care: *Curative* Histology _____ Stage: _____ Actionable biomarkers: _____

ONLY Checked care is in your care plan		Approximate time, order by month				
		month 1	m2	m3	m4	... m9+
Planning and Preparation						
<input type="checkbox"/>	Medical oncology consult, care planning	█				
<input type="checkbox"/>	Surgeon consult	█				
<input type="checkbox"/>	Complete tests and imaging	█				
<input type="checkbox"/>	Pulmonary function test (PFT)	█				
<input type="checkbox"/>	Fertility consult, treatment	█				
<input type="checkbox"/>	Clinical trial discussion, enrollment	█				
Prepare yourself and your health for treatment, start, then continue during treatment						
<input type="checkbox"/>	Support: emotional, transportation, food, other	█	█	█	█	█
<input type="checkbox"/>	Financial, health insurance, copay assistance	█	█	█	█	█
<input type="checkbox"/>	Get help to stop smoking, vaping, using tobacco	█	█	█	█	█
<input type="checkbox"/>	Get help to stop or limit alcohol	█	█	█	█	█
<input type="checkbox"/>	See primary care: checkup, current medications	█				
<input type="checkbox"/>	Discuss falls, frailty and memory concerns	█				
<input type="checkbox"/>	Get vaccines: Flu, PCV/PPSV, other	█				
<input type="checkbox"/>	See dentist if overdue for exam, cleaning	█				
<input type="checkbox"/>	Get nutrition information or consult	█				
<input type="checkbox"/>	Health Power of Attorney in medical records	█				
Cancer drug therapy						
<input type="checkbox"/>	Finalize therapy plan	█				
<input type="checkbox"/>	Port placement, if needed	█				
<input type="checkbox"/>	Medication to take before cancer treatment	█				
<input type="checkbox"/>	Medication to have on hand before chemo; do not start these yet	█				
<input type="checkbox"/>	Anti-cancer therapy consent and education	█				
<input type="checkbox"/>	Use barrier contraception / condoms	█				
<input type="checkbox"/>	Cancer drug (systemic) therapy					
<input type="checkbox"/>	Chemotherapy		█	█	█	█
<input type="checkbox"/>	Immunotherapy		█	█	█	█
<input type="checkbox"/>	Targeted therapy		█	█	█	█
<input type="checkbox"/>	Side Effect Management 4Rplan.com/onc-se/		█	█	█	█
<input type="checkbox"/>	Medical oncology visits		█	█	█	█
<input type="checkbox"/>	Follow-up imaging				█	█
<input type="checkbox"/>	Other:				█	█
<input type="checkbox"/>	Surgery					█
<input type="checkbox"/>	Additional cancer drug therapy					█
<input type="checkbox"/>	Radiation therapy					█
<input checked="" type="checkbox"/>	Follow-up care					█

© Copyright 2014-2024. Executive Frameworks, Ltd. <https://caresequence.net/lung-neo/> LC NEO ADJ v.07.01.2024
This document provides no warranties regarding the accuracy or application of its content, disclaims responsibility for its use, and does not offer medical or legal advice. It does not endorse specific products or therapies, mandate medical care, or represent the standard of care. The information may not be continually updated, and it is not a substitute for the professional judgment of a treating provider. Provided "as is," it makes no express or implied warranties, assumes no responsibility for any harm arising from its use, and disclaims liability for errors or omissions.

Results: Referral rates significantly improved for all 7 metrics

Metric	% of Patients referred to this care		P value
	4R cohort (N=61)	Control cohort (N=112)	
Primary care and chronic care	88%	46%	0.03
Smoking Cessation for people who smoke	93% n=28	46% n=80	0.0001
Help with transportation and practical needs	76%	24%	0.0001
Emotional Support	74%	35%	0.0001
Nutrition consultation and/or resources	69%	29%	0.0001
Financial and co-pay support	76%	24%	0.0001
Information about side effects and self-management resources	92%	39%	0.0001

Statistical analyses used two-sided fisher's exact test



SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

Conclusions:

- Patients who received 4R Care Sequences[®] had improved referrals and receipt of supportive and social care
- Our team continues to refine the 4R Oncology[®] model to support patients in completing referrals and utilizing self-management resources and further improve the metrics

The 4R Care Sequences[®] and associated tools are available at no cost to cancer programs and patients



Conclusions

- Digital Health may be the future of PC
- Customized music can improve pain and anxiety perioperatively
- Older adults may benefit from nurse led geriatric assessments
- The 4R model of care can improve care pathways and supportive care referrals

